Autor: |
Qing Hao, Ruicen Li, Hancong Li, Shu Rui, Liting You, Lingyun Zhang, Yue Zhao, Peiheng Li, Yuanmin Li, Xinagyu Kong, Haining Chen, Xiuhe Zou, Feng Liu, Xiaofei Wang, Juan Zhou, Weihan Zhang, Libing Huang, Yang Shu, JiaYe Liu, Ronghao Sun, Chao Li, Jingqiang Zhu, Yong Jiang, Tao Wei, Kun Qian, Bing Bai, Yiguo Hu, Yong Peng, Lunzhi Dai, Carlos Caulin, Heng Xu, Zhihui Li, Jihwan Park, Han Luo, Binwu Ying |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
Advanced Science, Vol 11, Iss 13, Pp n/a-n/a (2024) |
Druh dokumentu: |
article |
ISSN: |
2198-3844 |
DOI: |
10.1002/advs.202306364 |
Popis: |
Abstract γδ T cells are evolutionarily conserved T lymphocytes that manifest unique antitumor efficacy independent of tumor mutation burden (TMB) and conventional human leukocyte antigen (HLA) recognition. However, the dynamic changes in their T cell receptor (TCR) repertoire during cancer progression and treatment courses remain unclear. Here, a comprehensive characterization of γδTCR repertoires are performed in thyroid cancers with divergent differentiation states through cross‐sectional studies. The findings revealed a significant correlation between the differentiation states and TCR repertoire diversity. Notably, highly expanded clones are prominently enriched in γδ T cell compartment of dedifferentiated patients. Moreover, by longitudinal investigations of the γδ T cell response to various antitumor therapies, it is found that the emergence and expansion of the Vδ2neg subset may be potentially associated with favorable clinical outcomes after post‐radiotherapeutic immunotherapy. These findings are further validated at single‐cell resolution in both advanced thyroid cancer patients and a murine model, underlining the importance of further investigations into the role of γδTCR in cancer immunity and therapeutic strategies. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|